Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry

被引：11
|
作者：
Kwon, D. H. [1 ]
Vashisht, R. [2 ,3 ]
Borno, H. T. [1 ,2 ]
Aggarwal, R. R. [1 ,2 ]
Small, E. J. [1 ,2 ]
Butte, A. J. [2 ,3 ]
Huang, F. W. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
[2] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA
[4] San Francisco VA Med Ctr, San Francisco, CA 94121 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 05期
关键词：
D O I：
10.1016/j.annonc.2021.01.067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：678 / 679
页数：2
相关论文
共 50 条
  • [41] Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer
    Ishizaka, Kazuhiro
    Machida, Tatsuya
    Kobayashi, Shuichiro
    Kanbe, Naoko
    Kitahara, Satoshi
    Yoshida, Ken-Ichiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (12) : 1071 - 1075
  • [42] Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
    Braga-Basaria, Milena
    Dobs, Adrian S.
    Muller, Denis C.
    Carducci, Michael A.
    John, Majnu
    Egan, Josephine
    Basaria, Shehzad
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3979 - 3983
  • [43] Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy
    Sevilla, C.
    Maliski, S. L.
    Kwan, L.
    Connor, S. E.
    Litwin, M. S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (03) : 237 - 243
  • [44] Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates
    T J Polascik
    Prostate Cancer and Prostatic Diseases, 2008, 11 : 13 - 19
  • [45] Bone health in men receiving androgen deprivation therapy for prostate cancer
    Eastham, James A.
    JOURNAL OF UROLOGY, 2007, 177 (01): : 17 - 24
  • [46] Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy
    Gedeborg, Rolf
    Loeb, Stacy
    Styrke, Johan
    Kiiski-Berggren, Ritva
    Garmo, Hans
    Stattin, Par
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (11) : 1925 - 1934
  • [47] Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? - A conceptual review
    Bylow, Kathryn
    Mohile, Supriya G.
    Stadler, Walter M.
    Dale, William
    CANCER, 2007, 110 (12) : 2604 - 2613
  • [48] Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy
    Morales, Alvaro
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (06): : 210 - 211
  • [49] NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
    Huang, Shu-Pin
    Chen, Yei-Tsung
    Chen, Lih-Chyang
    Lee, Cheng-Hsueh
    Huang, Chao-Yuan
    Yu, Chia-Cheng
    Lin, Victor C.
    Lu, Te-Ling
    Bao, Bo-Ying
    BIOMEDICINES, 2021, 9 (05)
  • [50] Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
    Hirata, Yu
    Shiota, Masaki
    Kobayashi, Takeshi
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Eto, Masatoshi
    PROSTATE INTERNATIONAL, 2019, 7 (04) : 166 - 170
12345